ESMO 2023 Insights: "innovaTV 301/ENGOT-cx12/GOG-3057 Study - Tisotumab Vedotin vs. Investigator’s Choice of Chemo in 2L/3L Recurrent or Metastatic Cervical Cancer"

0 views
December 13, 2023
Comments 0
Login to view comments. Click here to Login